{
  "docId": "019de077-58c2-77ec-8b05-6d27c4bb0498",
  "docSlug": "35a6e53e15f172ec3a7e4b1f473eaa42",
  "documentTitle": "Genprex | Investor Presentation Deck | 58 slides",
  "authorId": "genprex",
  "authorName": "Genprex",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 28,
  "pageCount": 58,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 4,
  "notes": "Clinical trial design slide for a pharmaceutical study.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-58c2-77ec-8b05-6d27c4bb0498/28",
  "deckHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498",
  "deckJsonHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498.json",
  "deckAnchorHref": "/decks/019de077-58c2-77ec-8b05-6d27c4bb0498#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.633,
        "x": 0.183,
        "y": 0.595
      },
      "kind": "diagram",
      "text": "Phase 1 Dose Escalation to Phase 2 Expansion process flow",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b30ea23-01a9-45d5-be0c-1e3acb8b2cdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.48,
        "x": 0.051,
        "y": 0.115
      },
      "kind": "list",
      "text": "Patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq® and chemotherapy; Fast Track Designation and Orphan Drug Designation; ~10 U.S. sites; ~62 patients (Phase 1: 12, Phase 2: 50); Phase 2 futility analysis at 18 weeks.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd02cb38-284d-4905-b08a-2ffcd00c0182",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.428,
        "x": 0.586,
        "y": 0.33
      },
      "kind": "paragraph",
      "text": "Reqorsa® in combination with Genentech, Inc.'s Tecentriq® for SCLC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64ad6fe6-89c0-41f5-a232-58ce67d5cc71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.296,
        "x": 0.652,
        "y": 0.148
      },
      "kind": "title",
      "text": "Acclaim-3",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c815628-2a15-4b78-b70a-cbab8cadbdd2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "06bd584b-77a2-4436-a1f5-364ed9fddb3c",
      "evidence": "The slide uses a horizontal arrow-based flow to represent clinical trial phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "fba14042-e1cc-44ad-974d-c9a2c1f21ee2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "Future vision and potential impact of Genprex's gene therapies",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}